Compare PCT & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PCT | GLPG |
|---|---|---|
| Founded | 2015 | 1999 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Environmental Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.1B |
| IPO Year | N/A | 2005 |
| Metric | PCT | GLPG |
|---|---|---|
| Price | $10.57 | $33.62 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 3 | 4 |
| Target Price | $13.67 | ★ $31.33 |
| AVG Volume (30 Days) | ★ 4.2M | 105.9K |
| Earning Date | 02-26-2026 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $5,660,000.00 | ★ $336,643,201.00 |
| Revenue This Year | N/A | $1.76 |
| Revenue Next Year | $723.85 | $0.49 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 10.31 |
| 52 Week Low | $5.40 | $22.36 |
| 52 Week High | $17.37 | $37.78 |
| Indicator | PCT | GLPG |
|---|---|---|
| Relative Strength Index (RSI) | 62.98 | 64.63 |
| Support Level | $9.88 | $32.39 |
| Resistance Level | $10.75 | $33.27 |
| Average True Range (ATR) | 0.51 | 0.67 |
| MACD | 0.22 | 0.05 |
| Stochastic Oscillator | 93.78 | 85.45 |
PureCycle Technologies Inc is a Florida-based corporation focused on commercializing a patented dissolution process to physically separate the polymer from other plastics, color, and contaminants (the Technology), originally developed by The Procter & Gamble Company (P&G), for restoring waste polypropylene into resin with near-virgin characteristics, called PureFive resin. PureFive resin represents the family of recycled resin products produced, including ultra-pure resin and other grades used for compounding to meet customer specifications, which has similar properties and applicability for reuse as virgin polypropylene. It has a single operating segment, which encompasses integrated business activities related to the recycling of polypropylene into resins.
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.